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Supplementary Note 1: Detailed instruction for Panel b and c of Fig. 1. 
 
Panel b explanation. Cells represent the ratio of the odds of being a disease case for the column disease in 
those from each row and the odds of each row disease cases in unrelated European-ancestry individuals. For 
example, the odds of person in the UKB with a GORD phenotype is 12 fold higher in those with PUD, compared 
to those without PUD. However, GORD is more common than PUD (11.7% vs. 3.5%) and so the odds of PUD is 
less common than in those without GORD, odds 0.77. Panel c explanation. Taking PUD as an example index 
disease. There are 7,545 PUD cases without any comorbidity for GORD, IBS and IBD. Among the GORD, IBS and 
PUD cases, we first removed individuals with at least two of the three diseases, e.g., there are 34,729 
individuals who have a GORD diagnosis and not IBS or IBD, amongst whom 3,124 individuals also have a PUD 
diagnosis. Similarly, there are 16,337 individuals who have a IBS diagnosis but not GORD or IBD, amongst 
whom 743 individuals also have a PUD diagnosis. Lastly, and there are 3,839 individuals who have an IBD 
diagnosis but not GORD or IBS, among whom 201 individuals also have a PUD diagnoses. We then used a two 
proportion Z test to test which disease is more prone to be comorbid with PUD by comparing the proportion in 
pairs (i.e., 3124/34729, 743/16337, 201/3839).  
 
Supplementary Note 2: Discussion of SNP-based heritability and genetic correlation of subgroup phenotypes 
for each of PUD, GORD and IBS. 
 
A previous study reported rs10512344 to be the only SNP associated at the level of  genome-wide significance 
(reported P = 3.6E-8) in females with IBS using UKB self-reported illness (Data Field: 20003) data1. However, 
the P value for this SNP in our analyses is 5.0E-5 (4.4E-7 in females, Supplementary Fig. 10b). Given that they 
used a self-report phenotype while we used a combination of self-reported, hospital admission and primary 
care diseases diagnoses, we conducted a sensitivity analysis. We first removed individuals with diagnosis 
records from at least two resources and identified individuals with a diagnosis record from only one resource. 
For each of the IBS, PUD and GORD, We then regenerated three subgroup phenotypes using cases from one-
resource diagnosis record and controls from the original phenotype (Supplementary Fig. 10a). We conducted 
GWAS analyses (Methods) and investigated the summary statistics for rs10512344 among the GWAS analyses 
of the original IBS phenotype and the three IBS subgroup phenotypes (Supplementary Fig. 10b). We also 
investigated the SNP-based heritability and genetic correlation among the three subgroup phenotypes for 
each of the IBS, PUD and GORD (Supplementary Fig. 10c-d and Supplementary Table 8-9). Results showed 
that the three subgroup phenotypes for each of IBS, PUD and GORD are highly genetically correlated with each 
other (Supplementary Fig. 10d and Supplementary Table 9) (and from simulation and theory this overlap is 
not a reflection of the use of shared controls2). Our results do not support a robust association of rs10512344 
with IBS. 
 
Supplementary Note 3: Sensitivity analysis for SNP-based heritability and genetic correlation analyses. 
 
As a sensitivity analysis, SNP-based heritability (ℎ!"#$ ) and genetic correlation (rg) analyses were conducted for 
PUD, GORD, IBS and IBD using the phenotypes generated after excluding individuals with more than one of the 
four gastrointestinal (GI) disorders (defined as sensitivity analysis phenotypes). The number of overlapped 
individuals for PUD, GORD, IBS and IBD case are in Supplementary Fig. 9a. As expected, the ℎ!"#$  estimates on 
the observed scale for these disorders were lower due to the excluded individuals from the cases of original 
phenotypes but still significantly different from zero (Supplementary Fig. 9b); conversion to liability scale is 
difficult after case exclusion as it contravenes underlying assumptions of the transformation. We then 
calculated the rg within sensitivity analysis phenotypes, between sensitivity analysis phenotypes with traits 
from LD Hub and nine psychiatric and neurologic diseases from published studies (Supplementary Fig. 9c) 
(genetic correlations are robust to case/control ascertainment strategies2). The rg within sensitivity analysis 
phenotypes showed high rg among PUD, GORD, IBS and all low non-statistically significant rg with IBD. The rg 
between GORD and PUD is 0.38 (SE = 0.08, P = 3.6E-6) and the rg between GORD and IBS is 0.47 (SE = 0.08, P = 
3.4E-10), which are lower to the original results. The rg between PUD and IBS is 0.25 (SE = 0.12, P = 0.034), of 
which the original rg is 0.49 (SE = 0.08, P = 2.0E-10). As shown in Supplementary Fig. 9d, the number of 
overlapped individuals for PUD and IBS is 1,740, however, we over-removed 4,751 individuals for PUD and 
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6,323 individuals for IBS due to the overlap with the other two GI disorders (GORD and IBD, shown in 
Supplementary Fig. 9a). The number of total PUD and IBS cases is 16,666 and 29,524 and these over-removed 
individuals occupy ~1/4 for PUD cases and ~1/5 for IBS cases, resulting in reducing power to estimate the rg. 
Thus we only removed the only 1,740 overlapped individuals for PUD and IBS and re-calculated the rg between 
PUD and IBS, as shown in Supplementary Fig. 9e. The rg is 0.33 (SE = 0.09, P = 3.0E-4). PUD, GORD and IBS 
sensitivity analyses phenotypes showed statistically significantly rg with depressive symptoms while there is no 
statistically significant rg between IBD and depressive symptoms. The ℎ!"#$  for sensitivity analyses phenotypes 
are in Supplementary Table 6. The rg within sensitivity analysis phenotypes and between sensitivity analysis 
phenotypes and traits from the nine published psychiatric and neurologic studies are in Supplementary Table 
7 and 11. The rg between sensitivity analysis phenotypes with traits from LD Hub are in Supplementary Data 4. 
 
Supplementary Note 4: Sensitivity analysis for Mendelian Randomization between major depression and 
PG+M. 
 
Given the statistically significant results between MD and PG+M from bidirectional GSMR analyses, we also 
conducted bidirectional MR analyses between MD and PG+M using the TwoSampleMR package 
(https://github.com/MRCIEU/TwoSampleMR). For each of MD and PG+M GWAS summary statistics, we first 
generated the independent loci using PLINK(v1.90b)3 (--clump-p1 5.0E-8 –clump-p2 5.0E-8 –clump-r2 0.01 –
clump-kb 1000) and the genotype data (8,545,065 SNPs with MAF > 0.01) of 20,000 randomly sampled 
unrelated European individuals from UKB as a LD reference. Only the most significant SNP across the MHC 
region was retained. For each of the genetic instruments (i.e., SNPs), we extracted the allele, effect size, 
standard error and P value from the exposure GWAS summary statistics. We also extracted the corresponding 
information from the outcome GWAS summary statistics for these genetic instruments. If a SNP was 
unavailable in the outcome GWAS summary statistics, we identified proxy SNP with a minimum LD r2 = 0.7. For 
each direction of potential influence, we combined MR estimates using inverse variance-weighted (IVW)4 
analysis, which essentially translates to a weighted regression of SNP-outcome effects on SNP-exposure effects 
where the intercept is constrained to zero. The IVW method will return an unbiased estimate if there is no or 
balanced horizontal pleiotropy. To account for this, we compared results from IVW method with results from 
MR Egger5 and weighted median method6, from which the estimates are known to be relatively robust to 
horizontal pleiotropy, though at the cost of reduced statistical power. To assess robustness of significant 
results, we also conducted the MR Egger intercept test for horizontal pleiotropy. We also applied MR-PRESSO7 
(Pleiotropy Residual Sum and Outlier) to detect and correct for any outliers reflecting likely pleiotropic biases 
for all reported results. The IVW results showed bidirectionally statistically significant results, of which the 
pattern is similar as the GSMR results (Supplementary Fig. 15). The MR-Egger intercept test showed no 
statistical significance, suggesting that there is no horizontal pleiotropy (Supplementary Table 22). There is no 
outliers being removed after MR-PRESSO analyses. LCV method8 is designed to separate confounders from 
causality and hence is more likely to differ from MR where there is a unidirectional MR result. We used the 
LCV method to explore the relationship between MD and PG+M, following the instructions from 
https://github.com/lukejoconnor/LCV. Briefly, we used the munged file from LDSC for MD and PG+M, together 
with the provided LD score from 1000 Genomes Europeans data (eur_w_ld_chr, MHC region removed), as 
input. After selecting SNPs with MAF > 0.05 and sorted the SNPs from GWAS summary statistics by genomic 
region, the RunLCV() function was used for analysis. As expected ,the genetic causality proportion is not 
significant for PG+M and MD because of the strong bidirectional significance (Supplementary Table 24). 
 
Supplementary Note 5: Sensitivity analysis for Mendelian Randomization between major depression and 
depression-removed sensitivity GI phenotypes. 
 
As sensitivity analyses, we removed the depression cases (the combined cases from the UKB eight depression 
phenotypes) from the five GI disorder phenotypes (defined as GI-DepComRMV phenotypes) and conducted 
GWAS analyses. We repeated LDSC genetic correlation and MR analyses between major depression and these 
five GI-DepComRMV phenotypes. All genetic correlation results retained a pattern that did not change our 
interpretation of the original results (Supplementary Table 25). The MR results showed similar pattern results 
for four GI-DepComRMV phenotypes (GORD, PG+M, IBS and IBD), although the major depression and PUD-
DepComRMV became non-significant (Supplementary Table 26). These analyses removed a very high number 
of cases and controls based on the combined eight depression phenotype cases from PUD and hence the 
magnitude of the standard errors of the estimates from these sensitivity analyses were large. To gain further 
insight, we regenerated eight PUD sensitivity phenotypes after removing the cases of each of the eight 
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depression phenotypes from PUD in turn and repeated MR analyses. The MR results were significant for seven 
of them, as shown in Supplementary Table 27. The MR result were non-significant when cases and controls 
were removed based on the GPpsy-seen a GP for nerves, anxiety, tension or depression in which only 59% of 





Supplementary Table 1. Case definition and number of cases for each phenotype in UK Biobank. 
Phenotypes UKB data field UKB data field 
description 




PUD 131591 Source of report of K25 
(gastric ulcer) 
20: Death register only 
21: Death register and other 
source(s) 
30: Primary care only 
31: Primary care and other 
source(s) 
40: Hospital admissions data 
only 
41: Hospital admissions data 
and other source(s) 
50: Self-report only 
51: Self-report and other 
source(s) 
16666 
131593 Source of report of K26 
(duodenal ulcer) 
131595 Source of report of K27 
(peptic ulcer, site 
unspecified) 
131597 Source of report of K28 
(gastrojejunal ulcer) 




















131591 Source of report of K25 
(gastric ulcer) 
131593 Source of report of K26 
(duodenal ulcer) 
131595 Source of report of K27 
(peptic ulcer, site 
unspecified) 
131597 Source of report of K28 
(gastrojejunal ulcer) 
41272 Operative procedures - 
OPCS4 
G24: Antireflux operations 
G25: Revision of antireflux 
operations 
6154 Medication for pain 
relief, constipation, 
heartburn 
4:Ranitidine (e.g. Zantac) 
5:Omeprazole (e.g. Zanprol) 
20003 Treatment/medication 
code 
Supplementary Table 1 
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Supplementary Table 2. Medications for peptic ulcer disease (PUD) and gastro-oesophageal reflux disease 
(GORD) in UK Biobank. 
Category Coding Active ingredient ATC code* 
Maalox tablet 1140865358 Aluminum Hydroxide, Magnesium 
Hydroxide, Simethicone 
A02A 
Mucogel suspension 1140865368 Aluminum Hydroxide, Magnesium 
Hydroxide 
A02A 





1140881324 Magnesium Trisilicate A02A 
Milk of magnesia 
suspension 
1140881550 Magnesium Hydroxide A02AA 
Magnesium 
carbonate 
1140881320 Magnesium Carbonate A02AA01 
Magnesium 
hydroxide 
1140881330 Magnesium Hydroxide A02AA04 
Rennie duo oral 
suspension 
1141166086 Calcium Carbonate A02AC01 





1140865366 Aluminum Hydroxide, Magnesium 
Hydroxide 
A02AF02 
Gastrocote liquid 1140881414 Sodium Bicarbonate, Aluminum 
Hydroxide, Alginic Acid, Magnesium 
Trisilicate 
A02AX 
Gastrocote s/f liquid 1140928346 Sodium Bicarbonate, Aluminum 
Hydroxide, Alginic Acid, Magnesium 
Trisilicate 
A02AX 





1141188426 Ranitidine A02BA 
Cimetidine 1140865426 Cimetidine A02BA01 
Tagamet 100 tablet 1140909500 Cimetidine A02BA01 
Ranitidine 1140879406 Ranitidine A02BA02 
Zantac 75 tablet 1140916980 Ranitidine A02BA02 
Famotidine 1140865608 Famotidine A02BA03 
Pepcid ac 
indigestion tablet 
1140909496 Famotidine A02BA03 
Nizatidine 1140865618 Nizatidine A02BA04 
Misoprostol 1140865628 Misoprostol A02BB01 
Omeprazole 1140865634 Omeprazole A02BC01 
Losec 10mg capsule 1140909578 Omeprazole A02BC01 
Pantoprazole 1140929012 Pantoprazole A02BC02 
Protium 20mg e/c 
tablet 
1141164616 Pantoprazole A02BC02 
Lansoprazole 1140864752 Lansoprazole A02BC03 
Zoton 15mg capsule 1140923688 Lansoprazole A02BC03 
Rabeprazole sodium 1141168584 Rabeprazole A02BC04 
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Pariet 10mg e/c 
tablet 
1141168590 Rabeprazole A02BC04 
Esomeprazole 1141177526 Esomeprazole A02BC05 
Nexium 20mg tablet 1141177532 Esomeprazole A02BC05 
Acidex oral 
suspension 
1141172224 Sodium Bicarbonate, Calcium Carbonate, 
Alginic Acid 
A02BX 
Sucralfate 1140865536 Sucralfate A02BX02 
Antepsin 1g tablet 1140865538 Sucralfate A02BX02 
Gaviscon liquid 1140865354 Sodium Bicarbonate, Calcium Carbonate, 
Alginic Acid 
A02BX13 
Topal tablet 1140865370 Aluminum Hydroxide, Magnesium 
Carbonate, Alginic Acid 
A02BX13 
* The Supplementary Data 1 of Wu et al.9 provides UKB medication classification based on Anatomical 
Therapeutic Chemical (ATC) Classification System10 and we extracted medications for PUD and GORD (the first 
two ATC level: A02) as listed above.
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Supplementary Table 3. Genome-wide significant SNPs associated with inflammatory bowel disease (IBD) in UK 
Biobank from BOLT-LMM11 association analyses. 
SNP CHR. BP A1/A2 A1 
Frequency 
OR P Reported 
SNP* 
PMID 
rs148844907 6 31628397 T/A 0.99 0.47 9.7E-41 rs17207986 20848476 
rs11581607 1 67707690 G/A 0.93 1.51 2.2E-24 rs11209026 21102463 
rs4655529 1 67698909 C/T 0.69 0.84 1.0E-21 rs7517847 17435756 
rs2836878 21 40465534 G/A 0.73 1.21 2.1E-21 rs2836878 18758464 
rs10737482 1 20173858 T/C 0.39 0.86 3.4E-16 rs6426833 19915572 
rs3024505 1 206939904 G/A 0.85 0.84 8.7E-15 rs3024505 21102463 
rs6017342 20 43065028 A/C 0.48 0.88 1.6E-14 rs6017342 19915572 
rs905634 1 200884985 C/T 0.69 1.14 7.8E-13 rs11584383 18587394 
rs6671847 1 161478810 G/A 0.49 1.13 1.6E-12 rs1801274 19915573 
rs1297261 21 16812623 T/C 0.57 1.13 1.6E-12 rs1736020 21102463 
rs10761659 10 64445564 A/G 0.46 0.89 9.7E-12 rs10761659 21102463 
rs11403745 10 101282604 C/CA 0.48 1.12 2.1E-11 rs4409764 21102463 
rs35788599 12 68476749 G/C 0.62 0.89 3.2E-11 rs7134599 21297633 
rs7936312 11 76293726 G/T 0.52 0.90 6.7E-11 rs7927997 21102463 
rs10799837 1 20135612 G/A 0.43 1.12 1.6E-10 rs1317209 20228799 
9:5057580 9 5057580 CTTT/C 0.56 0.90 5.4E-10 rs10758669 21102463 
rs4551125 5 40438684 G/A 0.39 0.90 7.5E-10 rs11742570 21102463 
rs59998884 21 45618114 T/C 0.40 1.11 1.0E-09 rs2838519 21102463 
rs2066847 16 50763778 G/GC 0.98 0.71 1.7E-09 rs2066847 20570966 
rs17264332 6 138005515 A/G 0.78 0.89 2.5E-09 rs6920220 21297633 
rs3806306 1 20143100 A/G 0.62 1.11 2.6E-09 rs3806308 19122664 
rs55722650 5 131607300 C/T 0.58 0.90 4.5E-09 rs12521868 21102463 
rs6961243 7 107521404 G/A 0.59 1.11 5.0E-09 rs886774 19915572 
rs1521186 1 151784547 G/A 0.55 0.91 7.8E-09 - - 
rs13384671 2 182311594 A/G 0.69 0.90 9.0E-09 rs6740847 28067908 
5:17098189 5 17098189 AT/A 0.78 1.13 1.1E-08 - - 
rs73370726 10 90852873 C/T 0.90 1.19 1.5E-08 - - 
rs12720356 19 10469975 A/C 0.90 0.86 2.3E-08 rs12720356 21102463 
rs12568930 1 22702231 T/C 0.82 1.14 2.6E-08 rs7524102 21297633 
rs142738614 7 128577914 C/CGCGGG 0.55 0.91 3.3E-08 rs4728142 21297633 
rs10188217 2 61217542 T/C 0.48 0.91 4.3E-08 rs10181042 21102463 
* The associations between SNPs from “Reported SNP” column and IBD have been reported by other studies 
(corresponding PMID column). These SNPs are either same as IBD-associated SNPs in our UK Biobank analysis 
or in linkage disequilibrium with our IBD-associated SNPs in UK Biobank. For the detailed statistics for those 
reported SNPs, please refer to Supplementary Data 1. 
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Supplementary Table 4. Genome-wide significant SNPs associated with GORD and PG+M in the UK Biobank from BOLT-LMM11 association analyses. 
Digestion 
phenotypes 
SNP* CHR. BP A1/A2 A1 
frequency 





GORD rs2523589 6 31327334 G/T 0.50 0.95 4.6E-13 - § 
rs967823 17 50317276 A/G 0.61 0.96 1.6E-10 - - 
rs1430788 2 67868412 C/T 0.31 1.04 8.4E-09 - - 
PG+M rs200964 6 27866943 G/C 0.81 1.05 3.0E-13 - § 
rs967823 17 50317276 A/G 0.61 0.96 2.4E-12 - - 
rs10500661 11 6273744 T/C 0.80 0.96 9.7E-12 - - 





rs2861694 2 67845739 A/G 0.31 1.04 1.0E-10 - - 
rs12631337 3 50198537 A/G 0.45 1.03 1.5E-10 - SCZ, depressive 
symptoms and 
depressed affect 
rs61787782 1 98310239 A/G 0.78 0.96 8.1E-10 - SCZ, ADHD, ASD, 
anorexia 
nervosa, etc. 
2:100485494 2 100485494 CCCTCTG/C 0.64 1.03 1.9E-09 - - 
rs10641969 4 140940097 T/TCAA 0.62 1.03 3.1E-09 - - 
rs62435650 7 1823265 A/G 0.80 1.04 3.9E-09 - Depression, 
depressed affect 
and BIP 
rs12064884 1 66364651 A/G 0.50 1.03 5.2E-09 - ADHD, stress-
related 
disorders, etc. 






rs1873914 12 56379427 G/C 0.58 1.03 4.8E-08 - Anorexia 
nervosa 
* Locus zoom plot for SNPs are in Supplementary Fig. 5-6. 
† Odds ratio (OR) is for risk of A1 allele compared to A2 allele. 
‡ We only annotated SNPs if there are SNPs reported associated with either mental health-related traits or digestive diseases from GWAS Catalog12 in linkage disequilibrium 
with our UKB digestion SNPs (see Methods and Supplementary Data 1 for detailed description). “§” represents that SNP is within MHC region. For SNPs within MHC region 
see Supplementary Data 1 for details given the complexity of MHC region. 
Abbreviations: ASD: Autism spectrum disorder; BIP: Bipolar disorder; SCZ: Schizophrenia; ADHD: Attention deficit hyperactivity disorder. 
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Supplementary Table 5. GERA peptic ulcer and irritable bowel syndrome (IBS) GWAS summary statistics for SNPs associated with UKB peptic ulcer diseases and IBS (P < 5e-
8). 









Power† A1/A2 A1 
frequency 
OR* P 
PUD rs681343 19 49206462 C/T 0.49 0.92 1.9E-
15 
0.05/8 1004/60843 0.26 C/T 0.51 0.84 5E-4 
rs2976388 8 143760256 G/A 0.58 1.09 1.8E-
14 
0.27 G/A 0.57 1.07 0.12 
rs10500661 11 6273744 T/C 0.80 0.90 4.1E-
14 
0.29 T/C 0.79 0.90 0.08 
rs147048677 1 155161794 C/T 0.94 0.86 9.0E-
12 
0.20 C/T 0.95 0.87 0.20 
rs78459074 11 1029905 A/G 0.89 1.12 2.6E-
10 
0.17 - - - - 
rs34074411 17 39867248 C/T 0.56 0.93 2.6E-
10 
0.19 - - - - 
rs687621 9 136137065 A/G 0.68 1.08 1.3E-
09 
0.18 A/G 0.66 1.13 0.02 
rs9581957 13 28557889 C/T 0.68 0.93 3.6E-
09 
0.17 C/T 0.68 0.96 0.41 
IBS rs7947502 11 112909396 C/T 0.41 1.05 2.5E-
08 
0.05/2 3359/58488 0.48 C/T 0.41 1.04 0.14 
rs2523599 6 31241092 C/G 0.39 0.95 4.4E-
08 
0.51 - - - - 
* Odds ratio (OR) is for risk of A1 allele compared to A2 allele. 
† Power to detect SNPs with statistical significance at an alpha level and the GERA sample size. The power for each SNP were calculated using RPower package13. Since the 
average power for the PUD SNPs is 20%, identifying 1 in 6 available for testing in line with these power calculations. 
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λGC* Intercept (s.e.) h2_observed (s.e.) Population 
lifetime risk† 
h2_liability (s.e.) 
PUD 1.10 1.01 (0.007) 0.01 (0.001) 0.037 0.06 (0.007) 
GORD 1.25 1.02 (0.008) 0.03 (0.002) 0.120 0.08 (0.004) 
PG+M 1.43 1.04 (0.008) 0.05 (0.002) 0.198 0.09 (0.003) 
IBS 1.15 1.00 (0.007) 0.02 (0.001) 0.063 0.06 (0.005) 
IBD 1.11 1.03 (0.008) 0.01 (0.002) 0.015 0.11 (0.016) 
PUD (RO)‡ 1.05 1.01 (0.006) 0.006 (0.001) 0.023 0.046 (0.008) 
GORD (RO) 1.20 1.02 (0.008) 0.022 (0.001) 0.095 0.066 (0.004) 
IBS (RO) 1.05 1.00 (0.007) 0.008 (0.001) 0.046 0.038 (0.006) 
IBD (RO) 1.10 1.03 (0.008) 0.008 (0.002) 0.012 0.096 (0.018) 
PUD (RTO) 1.10 1.01 (0.007) 0.009 (0.001) 0.033 0.050 (0.007) 
IBS (RTO) 1.10 1.01 (0.007) 0.013 (0.001) 0.059 0.052 (0.005) 
* The calculation for λGC is from LD score regression. 
† We used the proportion of sample that are cases as the estimates of population lifetime. 
‡ We note that the case ascertainment for RO and RTO ascertainment means that assumptions underlying 
conversion of SNP-based heritabilities to the liability scale may be violated.  
Abbreviation: s.e.: standard error; RO: remove individuals with more than one of PUD, GORD, IBS and IBD 
disorders; RTO: remove the overlapped individuals with both PUD and IBS.  
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Supplementary Table 7. Genetic correlation estimates for each pair of the five original digestion phenotypes 
and each pair of the five sensitivity digestion phenotypes from bivariate LD score regression analysis15. (see 
Fig. 4b and Supplementary Fig. 9c1) 
Trait1 Trait2 rg se p gcov int* gcov int se 
PUD GORD 0.65 0.052 4.9E-36 0.12 0.005 
PUD PG+M 0.76 0.036 5.1E-101 0.40 0.006 
PUD IBS 0.49 0.077 2.0E-10 0.04 0.005 
PUD IBD 0.07 0.084 3.7E-01 0.03 0.006 
GORD PUD 0.65 0.052 4.9E-36 0.12 0.005 
GORD PG+M 0.97 0.008 0.0E+00 0.77 0.007 
GORD IBS 0.65 0.045 1.1E-46 0.10 0.005 
GORD IBD 0.19 0.056 9.0E-04 0.02 0.005 
PG+M PUD 0.76 0.036 5.1E-101 0.40 0.006 
PG+M GORD 0.97 0.008 0.0E+00 0.77 0.007 
PG+M IBS 0.64 0.040 1.4E-57 0.11 0.006 
PG+M IBD 0.19 0.048 1.0E-04 0.03 0.006 
IBS PUD 0.49 0.077 2.0E-10 0.04 0.005 
IBS GORD 0.65 0.045 1.1E-46 0.10 0.005 
IBS PG+M 0.64 0.040 1.4E-57 0.11 0.006 
IBS IBD 0.02 0.070 7.6E-01 -0.02 0.005 
IBD PUD 0.07 0.084 3.7E-01 0.03 0.006 
IBD GORD 0.19 0.056 9.0E-04 0.02 0.005 
IBD PG+M 0.19 0.048 1.0E-04 0.03 0.006 
IBD IBS 0.02 0.070 7.6E-01 -0.02 0.005 
PUD (RO)† GORD (RO) 0.38 0.082 3.6E-06 -0.05 0.005 
PUD (RO) IBS (RO) 0.25 0.117 3.4E-02 -0.03 0.005 
PUD (RO) IBD (RO) -0.12 0.120 3.4E-01 -0.02 0.005 
GORD (RO) PUD (RO) 0.38 0.082 3.6E-06 -0.05 0.005 
GORD (RO) IBS (RO) 0.47 0.075 3.4E-10 -0.08 0.005 
GORD (RO) IBD (RO) 0.02 0.075 7.8E-01 -0.04 0.005 
IBS (RO) PUD (RO) 0.25 0.117 3.4E-02 -0.03 0.005 
IBS (RO) GORD (RO) 0.47 0.075 3.4E-10 -0.08 0.005 
IBS (RO) IBD (RO) -0.08 0.101 4.4E-01 -0.01 0.005 
IBD (RO) PUD (RO) -0.12 0.120 3.4E-01 -0.02 0.005 
IBD (RO) GORD (RO) 0.02 0.075 7.8E-01 -0.04 0.005 
IBD (RO) IBS (RO) -0.08 0.101 4.4E-01 -0.01 0.005 
* In LD score regression the sample overlap is partitioned into the gcov_int (the genetic covariance intercept) 
for which the expected value is phenotypic correlation * proportion of shred individuals between the two 
GWAS datasets contributing to the LDSC genetic correlation analysis. 
† RO: remove individuals with more than one of PUD, GORD, IBS and IBD disorders.
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Supplementary Table 8. SNP-based heritability estimates and other parameters from LD score regression14 for 
self-report, primary care and hospital admission subgroup phenotypes for each of PUD, GORD and IBS. (see 
Supplementary Fig. 10c) 
Digestion 
Phenotypes 
λGC* Intercept (s.e.) h2_observed (s.e.) Population 
lifetime risk† 
h2_liability (s.e.) 




1.05 1.01 (0.006) 0.003 (0.001) 0.016 0.052 (0.017) 
PUD Self 
Report 
1.05 1.01 (0.007) 0.004 (0.001) 0.008 0.068 (0.020) 
PUD Primary 
Care 
1.05 1.01 (0.006) 0.003 (0.001) 0.007 0.028 (0.010) 




1.10 1.00 (0.007) 0.011 (0.001) 0.054 0.065 (0.008) 
GORD Self 
Report 




1.15 1.01 (0.007) 0.015 (0.001) 0.018 0.063 (0.006) 
IBS 1.15 1.00 (0.007) 0.015 (0.001) 0.063 0.057 (0.005) 
IBS Hospital 
Admission 
1.05 1.00 (0.007) 0.005 (0.001) 0.009 0.049 (0.012) 
IBS Self 
Report 
1.05 1.01 (0.006) 0.005 (0.001) 0.016 0.035 (0.008) 
IBS Primary 
Care 
1.05 1.00 (0.007) 0.004 (0.001) 0.029 0.052 (0.015) 
* The calculation for λGC is from LD score regression. 
† We used the proportion of sample that are cases as the estimates of population lifetime. 
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Supplementary Table 9. Genetic correlation among self-report, primary care and hospital admission subgroup 
phenotypes for each of PUD, GORD and IBS from bivariate LD score regression analysis15. (see Supplementary 
Fig. 10d) 
Trait1 Trait2 rg se p gcov_int* gcov_int_se 
PUD Hospital Admission PUD Primary Care 0.94 0.299 1.6E-03 0.01 0.005 
PUD Hospital Admission PUD Self Report 0.81 0.312 9.7E-03 0.02 0.005 
PUD Hospital Admission PUD 1.06 0.111 2.2E-21 0.66 0.005 
PUD Primary Care PUD Hospital Admission 0.94 0.299 1.6E-03 0.01 0.005 
PUD Primary Care PUD Self Report 0.49 0.230 3.3E-02 0.02 0.005 
PUD Primary Care PUD 0.89 0.099 2.9E-19 0.44 0.005 
PUD Self Report PUD Hospital Admission 0.81 0.312 9.7E-03 0.02 0.005 
PUD Self Report PUD Primary Care 0.49 0.230 3.3E-02 0.02 0.005 
PUD Self Report PUD 0.82 0.104 2.8E-15 0.48 0.005 
PUD PUD Hospital Admission 1.06 0.111 2.2E-21 0.66 0.005 
PUD PUD Primary Care 0.89 0.099 2.9E-19 0.44 0.005 
PUD PUD Self Report 0.82 0.104 2.8E-15 0.48 0.005 
GORD Hospital Admission GORD Primary Care 0.80 0.146 4.1E-08 0.03 0.005 
GORD Hospital Admission GORD Self Report 0.78 0.079 1.8E-23 0.05 0.005 
GORD Hospital Admission GORD 0.97 0.020 0.0E+00 0.68 0.006 
GORD Primary Care GORD Hospital Admission 0.80 0.146 4.1E-08 0.03 0.005 
GORD Primary Care GORD Self Report 0.62 0.161 1.0E-04 0.03 0.005 
GORD Primary Care GORD 0.86 0.105 3.4E-16 0.40 0.005 
GORD Self Report GORD Hospital Admission 0.78 0.079 1.8E-23 0.05 0.005 
GORD Self Report GORD Primary Care 0.62 0.161 1.0E-04 0.03 0.005 
GORD Self Report GORD 0.89 0.037 7.9E-129 0.53 0.006 
GORD GORD Hospital Admission 0.97 0.020 0.0E+00 0.68 0.006 
GORD GORD Primary Care 0.86 0.105 3.4E-16 0.40 0.005 
GORD GORD Self Report 0.89 0.037 7.9E-129 0.53 0.006 
IBS Hospital Admission IBS Primary Care 0.85 0.212 5.8E-05 0.01 0.005 
IBS Hospital Admission IBS Self Report 0.71 0.210 7.0E-04 0.02 0.005 
IBS Hospital Admission IBS 1.01 0.119 1.8E-17 0.35 0.005 
IBS Primary Care IBS Hospital Admission 0.85 0.212 5.8E-05 0.01 0.005 
IBS Primary Care IBS Self Report 0.63 0.158 5.8E-05 0.02 0.005 
IBS Primary Care IBS 0.94 0.052 1.2E-74 0.67 0.005 
IBS Self Report IBS Hospital Admission 0.71 0.210 7.0E-04 0.02 0.005 
IBS Self Report IBS Primary Care 0.63 0.158 5.8E-05 0.02 0.005 
IBS Self Report IBS 0.79 0.068 1.1E-31 0.50 0.006 
IBS IBS Hospital Admission 1.01 0.119 1.8E-17 0.35 0.005 
IBS IBS Primary Care 0.94 0.052 1.2E-74 0.67 0.005 
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IBS IBS Self Report 0.79 0.068 1.1E-31 0.50 0.006 
* In LD score regression the sample overlap is partitioned into the gcov_int (the genetic covariance intercept) 
for which the expected value is phenotypic correlation * proportion of shred individuals between the two 
GWAS datasets contributing to the LDSC genetic correlation analysis. 
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Supplementary Table 10. Genetic correlation estimates between each of the five digestion phenotypes and 9 
psychiatric and neurological traits from bivariate LD score regression analysis15. (see Fig. 4b) 










PUD ADHD† 0.48 0.057 9.1E-17 0.24 0.016 1.03 0.010 0.01 0.006 
Schizophrenia 0.13 0.040 1.0E-03 0.42 0.015 1.05 0.012 0.00 0.006 
Anxiety 0.26 0.179 1.5E-01 0.06 0.026 1.00 0.007 0.00 0.005 
PTSD 0.30 0.164 7.2E-02 0.05 0.022 0.99 0.007 0.00 0.005 
Bipolar 
disorder 




0.00 0.066 9.7E-01 0.20 0.015 1.00 0.008 0.00 0.006 
Alzheimer’s 
disease 
0.08 0.093 4.0E-01 0.01 0.005 1.06 0.052 0.00 0.005 
Parkinson's 
disease 




0.37 0.045 2.1E-16 0.06 0.003 1.01 0.010 0.01 0.006 
GORD ADHD 0.49 0.036 3.1E-42 0.24 0.016 1.03 0.010 0.00 0.006 
Schizophrenia 0.03 0.027 2.4E-01 0.42 0.015 1.05 0.012 0.01 0.006 
Anxiety 0.30 0.127 1.7E-02 0.06 0.026 1.00 0.007 0.01 0.005 
PTSD 0.23 0.119 4.8E-02 0.05 0.022 0.99 0.007 0.00 0.005 
Bipolar 
disorder 




-0.01 0.043 8.6E-01 0.20 0.015 1.00 0.008 0.01 0.006 
Alzheimer’s 
disease 
0.01 0.059 9.0E-01 0.01 0.005 1.06 0.052 0.01 0.006 
Parkinson's 
disease 




0.37 0.027 3.3E-41 0.06 0.003 1.01 0.010 0.01 0.006 
PG+M ADHD 0.56 0.032 5.0E-66 0.24 0.016 1.03 0.010 0.01 0.007 
Schizophrenia 0.04 0.024 1.1E-01 0.42 0.015 1.05 0.012 0.01 0.007 
Anxiety 0.37 0.132 5.5E-03 0.06 0.026 1.00 0.007 0.01 0.005 
PTSD 0.30 0.107 4.3E-03 0.05 0.022 0.99 0.007 0.00 0.005 
Bipolar 
disorder 




0.06 0.039 1.4E-01 0.20 0.015 1.00 0.008 0.01 0.006 
Alzheimer’s 
disease 
-0.03 0.050 6.0E-01 0.01 0.005 1.06 0.052 0.01 0.006 
Parkinson's 
disease 




0.43 0.024 1.4E-74 0.06 0.003 1.01 0.010 0.01 0.006 
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IBS ADHD 0.30 0.057 1.8E-07 0.24 0.016 1.03 0.010 0.00 0.006 
Schizophrenia 0.15 0.036 3.2E-05 0.42 0.015 1.05 0.012 0.00 0.007 
Anxiety 0.30 0.152 4.9E-02 0.06 0.026 1.00 0.007 0.00 0.005 
PTSD 0.34 0.182 6.2E-02 0.05 0.022 0.99 0.007 0.00 0.005 
Bipolar 
disorder 




0.21 0.061 7.0E-04 0.20 0.015 1.00 0.008 -0.01 0.005 
Alzheimer’s 
disease 
0.05 0.085 5.7E-01 0.01 0.005 1.06 0.052 0.01 0.005 
Parkinson's 
disease 




0.49 0.042 1.1E-31 0.06 0.003 1.01 0.010 0.01 0.006 
IBD ADHD 0.00 0.059 9.6E-01 0.24 0.016 1.03 0.010 0.01 0.006 
Schizophrenia 0.04 0.040 3.7E-01 0.42 0.015 1.05 0.012 0.00 0.006 
Anxiety 0.23 0.148 1.2E-01 0.06 0.026 1.00 0.007 0.00 0.005 
PTSD 0.20 0.161 2.1E-01 0.05 0.022 0.99 0.007 0.00 0.005 
Bipolar 
disorder 




-0.05 0.059 3.8E-01 0.20 0.015 1.00 0.008 0.01 0.005 
Alzheimer’s 
disease 
-0.05 0.092 5.9E-01 0.01 0.005 1.06 0.052 0.00 0.005 
Parkinson's 
disease 




0.15 0.043 3.0E-04 0.06 0.003 1.01 0.010 0.00 0.005 
* In LD score regression the sample overlap is partitioned into the gcov_int (the genetic covariance intercept) 
for which the expected value is phenotypic correlation * proportion of shred individuals between the two 
GWAS datasets contributing to the LDSC genetic correlation analysis. 
† Cells highlighted with yellow represent that genetic correlation are still significant after Bonferroni 
correction.
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Supplementary Table 11. Genetic correlation estimates between each of the five sensitivity analyses 
phenotypes and 9 psychiatric and neurologic traits from bivariate LD score regression analysis15. (see 
Supplementary Fig. 9c) 
Trait1* Trait2 rg se p gcov int† gcov int se 
PUD (RO) ADHD 0.40 0.077 1.8E-07 0.01 0.006 
Schizophrenia 0.06 0.050 2.0E-01 0.00 0.006 
Anxiety 0.34 0.228 1.4E-01 0.00 0.005 
PTSD 0.36 0.223 1.1E-01 0.00 0.005 




0.03 0.073 7.1E-01 0.00 0.005 
Alzheimer’s 
disease 
-0.02 0.112 8.6E-01 0.01 0.005 
Parkinson's 
disease 
-0.02 0.074 7.6E-01 0.01 0.004 
Major 
depression 2018 
0.34 0.059 1.2E-08 0.00 0.005 
GORD (RO) ADHD 0.47 0.042 3.1E-29 0.00 0.006 
Schizophrenia -0.01 0.029 6.9E-01 0.01 0.006 
Anxiety 0.27 0.133 3.9E-02 0.01 0.005 
PTSD 0.12 0.123 3.1E-01 0.00 0.005 




0.00 0.048 9.3E-01 0.01 0.006 
Alzheimer’s 
disease 
-0.05 0.064 4.1E-01 0.01 0.006 
Parkinson's 
disease 
-0.08 0.044 6.7E-02 0.00 0.005 
Major 
depression 2018 
0.33 0.031 1.4E-27 0.01 0.005 
IBS (RO) ADHD 0.20 0.071 4.3E-03 0.00 0.006 
Schizophrenia 0.16 0.048 1.0E-03 -0.01 0.006 
Anxiety 0.31 0.193 1.1E-01 0.00 0.005 
PTSD 0.14 0.208 5.1E-01 0.01 0.005 




0.33 0.074 6.7E-06 -0.01 0.005 
Alzheimer’s 
disease 
-0.04 0.119 7.2E-01 0.01 0.005 
Parkinson's 
disease 
0.14 0.073 5.9E-02 0.00 0.005 
Major 
depression 2018 
0.49 0.057 6.5E-18 0.00 0.006 
IBD (RO) ADHD -0.09 0.069 1.8E-01 0.01 0.006 
Schizophrenia 0.02 0.043 6.8E-01 0.00 0.006 
Anxiety 0.25 0.168 1.4E-01 0.00 0.005 
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PTSD 0.10 0.186 6.0E-01 0.00 0.005 




-0.06 0.065 3.7E-01 0.00 0.005 
Alzheimer’s 
disease 
-0.06 0.110 5.8E-01 0.00 0.005 
Parkinson's 
disease 
-0.08 0.074 2.6E-01 0.00 0.005 
Major 
depression 2018 
0.11 0.050 3.4E-02 0.00 0.006 
* RO: remove individuals with more than one of PUD, GORD, IBS and IBD disorders. 
† In LD score regression the sample overlap is partitioned into the gcov_int (the genetic covariance intercept) 
for which the expected value is phenotypic correlation * proportion of shred individuals between the two 
GWAS datasets contributing to the LDSC genetic correlation analysis. 
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Supplementary Table 12. Results of partitioning SNP-based heritability analysis16 for GORD, PG+M, IBS and IBD 
by functional annotation based on the variants within each category after Bonferroni correction. (see 
Supplementary Fig. 11) 







GORD Conserved 0.03 0.39 0.067 14.90 2.553 1.2E-07 
Conserved 
(extend 500) 
0.33 0.58 0.063 1.75 0.190 1.2E-04 
H3K4me1 (extend 
500) 
0.61 0.93 0.061 1.53 0.100 2.1E-06 
PG+M Conserved 0.03 0.38 0.045 14.60 1.722 1.6E-13 
Conserved 
(extend 500) 
0.33 0.61 0.048 1.85 0.145 2.2E-08 
DHS (extend 500) 0.50 0.85 0.067 1.71 0.134 8.0E-07 
Fetal DHS 0.08 0.34 0.067 4.05 0.792 1.4E-04 
Fetal DHS (extend 
500) 
0.29 0.59 0.064 2.06 0.223 5.5E-06 
H3K27ac 0.39 0.51 0.031 1.31 0.078 1.6E-04 
H3K27ac PGC2 
(extend 500) 
0.34 0.52 0.045 1.53 0.134 1.0E-04 
H3K4me1 (extend 
500) 
0.61 0.91 0.042 1.49 0.068 1.0E-10 
H3K4me3 0.13 0.34 0.048 2.54 0.361 2.0E-05 
H3K9ac 0.13 0.37 0.051 2.90 0.404 2.6E-06 
H3K9ac (extend 
500) 
0.23 0.48 0.051 2.07 0.223 4.8E-06 
Intron 0.39 0.49 0.023 1.25 0.059 1.9E-05 
Intron (extend 
500) 
0.40 0.47 0.020 1.19 0.050 1.6E-04 
Repressed 
(extend 500) 
0.72 0.61 0.028 0.85 0.039 1.7E-04 
Super Enhancer 0.17 0.24 0.018 1.45 0.108 5.4E-05 
Super Enhancer 
(extend 500) 
0.17 0.25 0.019 1.48 0.109 2.2E-05 
IBS Conserved 0.03 0.51 0.098 19.61 3.761 1.2E-06 
Conserved 
(extend 500) 
0.33 0.82 0.110 2.47 0.331 8.8E-06 
IBD Enhancer (extend 
500) 
0.15 0.71 0.137 4.64 0.888 5.7E-05 
H3K27ac 0.39 0.95 0.100 2.43 0.256 5.9E-10 
H3K27ac (extend 
500) 
0.42 1.00 0.108 2.37 0.255 7.5E-09 
H3K4me1 (extend 
500) 
0.61 1.03 0.095 1.69 0.156 4.0E-05 
H3K4me3 0.13 0.76 0.178 5.71 1.334 1.4E-04 
Repressed 
(extend 500) 
0.72 0.24 0.085 0.33 0.118 1.1E-10 
Super Enhancer 0.17 0.54 0.068 3.20 0.404 9.0E-09 
Super Enhancer 
(extend 500) 
0.17 0.62 0.062 3.64 0.362 7.7E-14 
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Supplementary Table 13. Results of partitioning SNP-based heritability analysis for PUD, GORD, PG+M, IBS, IBD 
and PG+M (sensitivity analysis after conditioning on other traits) by cell group functional annotations16. (see 
Fig. 5a) 






PUD Adrenal Pancreas 0.09 0.36 0.104 3.83 1.108 1.2E-02 
Central Nervous 
System 
0.15 0.47 0.109 3.16 0.734 3.5E-03 
Gastrointestinal 0.17 0.54 0.129 3.24 0.767 4.2E-03 
Immune 0.23 0.44 0.122 1.90 0.521 8.7E-02 
Liver 0.07 0.25 0.084 3.53 1.160 2.9E-02 
GORD  Adrenal Pancreas 0.09 0.26 0.047 2.81 0.504 5.2E-04 
Central Nervous 
System* 
0.15 0.38 0.046 2.52 0.310 2.1E-06 
Gastrointestinal 0.17 0.31 0.053 1.87 0.315 7.7E-03 
Immune 0.23 0.35 0.056 1.52 0.241 3.4E-02 
Liver 0.07 0.15 0.034 2.05 0.470 2.8E-02 
PG+M Adrenal Pancreas 0.09 0.27 0.037 2.91 0.394 2.1E-06 
Central Nervous 
System 
0.15 0.41 0.034 2.75 0.230 2.2E-13 
Gastrointestinal 0.17 0.30 0.040 1.79 0.237 1.2E-03 
Immune 0.23 0.39 0.040 1.65 0.171 1.9E-04 
Liver 0.07 0.16 0.027 2.22 0.374 1.2E-03 
IBS Adrenal Pancreas 0.09 0.31 0.085 3.35 0.908 8.2E-03 
Central Nervous 
System 
0.15 0.55 0.089 3.70 0.596 7.8E-06 
Gastrointestinal 0.17 0.31 0.106 1.84 0.631 1.8E-01 
Immune 0.23 0.39 0.114 1.67 0.487 1.6E-01 
Liver 0.07 0.20 0.068 2.82 0.936 5.0E-02 
IBD Adrenal Pancreas 0.09 0.42 0.105 4.51 1.123 9.9E-04 
Central Nervous 
System 
0.15 0.34 0.114 2.28 0.767 8.9E-02 
Gastrointestinal 0.17 0.73 0.140 4.37 0.833 3.3E-05 
Immune 0.23 1.00 0.139 4.30 0.596 5.7E-08 
Liver 0.07 0.24 0.078 3.26 1.078 3.6E-02 
PG+M 
(Conditional 




Adrenal Pancreas 0.09 0.28 0.039 3.04 0.42 2.4E-06 
Central Nervous 
System 
0.15 0.40 0.037 2.66 0.25 7.3E-11 
Gastrointestinal 0.17 0.31 0.046 1.87 0.28 2.2E-03 
Immune 0.23 0.39 0.051 1.69 0.22 1.7E-03 
Liver 0.07 0.16 0.032 2.18 0.44 8.2E-03 
* Cells highlighted with yellow represent that tissue are still significant after Bonferroni correction.
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Supplementary Table 14. Statistically significant results of partitioning SNP-based heritability of PG+M and IBD 
to 205 tissues/cell types after Bonferroni correction and PG+M (sensitivity analyses for 3 tissues after 
conditioning on other traits) using LDSC cell type specific expressed genes analysis17. (see Fig. 5b) 







IBD Leukocytes Blood/Immune 4.1E-09 1.0E-09 2.4E-05 4.62 
Blood Cells 3.8E-09 9.7E-10 3.8E-05 4.42 
PG+M Brain Hippocampus CNS 2.5E-09 6.4E-10 5.8E-05 4.24 
Brain Frontal Cortex 
(BA9) 




2.4E-09 6.4E-10 1.0E-04 3.98 
PG+M 
(Conditional 







CNS 1.7E-09 5.9E-10 0.002 2.70 
Brain Frontal Cortex 
(BA9) 
1.6E-09 5.7E-10 0.002 2.70 
Brain Hippocampus 1.7E-09 5.7E-10 0.002 2.70 
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Supplementary Table 15. Results of partitioning SNP-based heritability of five digestion phenotypes and PG+M 
(sensitivity analyses after conditioning on other traits) to final-scale GTEx brain expression data using LDSC cell 
type specific expressed genes analysis17. (see Fig. 5c) 
Trait Name Coefficient Coefficient s.e. Coefficient P value 
GORD Cortex* 2.1E-09 6.1E-10 3.7E-04 
Frontal Cortex (BA9) 1.4E-09 5.0E-10 2.2E-03 
Anterior cingulate cortex (BA24) 9.1E-10 5.0E-10 3.3E-02 
Cerebellum 1.1E-09 6.5E-10 4.6E-02 
Cerebellar Hemisphere 7.3E-10 6.4E-10 1.3E-01 
Amygdala -2.7E-11 5.8E-10 5.2E-01 
Hippocampus -1.2E-10 5.1E-10 5.9E-01 
Caudate (basal ganglia) -1.5E-10 5.7E-10 6.0E-01 
Putamen (basal ganglia) -3.5E-10 5.6E-10 7.3E-01 
Substantia nigra -4.9E-10 5.8E-10 8.0E-01 
Hypothalamus -4.5E-10 5.2E-10 8.1E-01 
Nucleus accumbens (basal 
ganglia) 
-5.0E-10 5.1E-10 8.4E-01 
Spinal cord (cervical c-1) -1.1E-09 5.8E-10 9.7E-01 
PG+M Cortex 3.1E-09 7.5E-10 2.3E-05 
Frontal Cortex (BA9) 2.2E-09 6.3E-10 2.4E-04 
Anterior cingulate cortex (BA24) 1.4E-09 6.4E-10 1.5E-02 
Cerebellum 1.5E-09 7.9E-10 2.5E-02 
Cerebellar Hemisphere 1.3E-09 7.6E-10 4.7E-02 
Nucleus accumbens (basal 
ganglia) 
5.5E-10 6.6E-10 2.0E-01 
Caudate (basal ganglia) -8.9E-11 7.2E-10 5.5E-01 
Spinal cord (cervical c-1) -2.7E-10 7.6E-10 6.4E-01 
Amygdala -3.8E-10 7.3E-10 7.0E-01 
Hippocampus -5.6E-10 6.4E-10 8.1E-01 
Hypothalamus -5.8E-10 6.3E-10 8.2E-01 
Substantia nigra -1.0E-09 6.8E-10 9.3E-01 
Putamen (basal ganglia) -1.4E-09 6.7E-10 9.8E-01 
IBS Cerebellum 7.4E-10 5.3E-10 8.1E-02 
Frontal Cortex (BA9) 5.9E-10 4.5E-10 9.7E-02 
Cortex 5.2E-10 5.1E-10 1.5E-01 
Cerebellar Hemisphere 2.9E-10 4.7E-10 2.6E-01 
Putamen (basal ganglia) 2.4E-10 4.8E-10 3.1E-01 
Hippocampus 1.4E-10 4.6E-10 3.8E-01 
Anterior cingulate cortex (BA24) -8.3E-12 4.5E-10 5.1E-01 
Caudate (basal ganglia) -5.6E-11 4.4E-10 5.5E-01 
Amygdala -2.8E-10 4.3E-10 7.4E-01 
Spinal cord (cervical c-1) -3.4E-10 4.2E-10 7.9E-01 
Nucleus accumbens (basal 
ganglia) 
-3.6E-10 4.3E-10 8.0E-01 
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Substantia nigra -6.5E-10 4.3E-10 9.3E-01 
Hypothalamus -1.0E-09 4.5E-10 9.9E-01 
PG+M 
(Conditional 
on EA, BMI 
and smoking 
traits) 
Cortex 2.6E-09 6.7E-10 4.2E-05 
Frontal Cortex (BA9) 1.9E-09 6.0E-10 7.1E-04 
Cerebellum 1.9E-09 7.0E-10 4.0E-03 
Anterior cingulate cortex (BA24) 1.3E-09 5.8E-10 1.5E-02 
Cerebellar Hemisphere 9.2E-10 6.7E-10 8.5E-02 
Nucleus accumbens (basal 
ganglia) 
-1.9E-13 5.7E-10 5.0E-01 
Amygdala -1.9E-10 6.4E-10 6.2E-01 
Spinal cord (cervical c-1) -3.5E-10 6.9E-10 6.9E-01 
Hypothalamus -3.6E-10 6.6E-10 7.1E-01 
Caudate (basal ganglia) -5.6E-10 6.1E-10 8.2E-01 
Hippocampus -5.9E-10 6.2E-10 8.3E-01 
Substantia nigra -7.6E-10 6.0E-10 9.0E-01 
Putamen (basal ganglia) -1.3E-09 5.6E-10 9.9E-01 
* Cells highlighted with yellow represent that tissue are still significant after Bonferroni correction.
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Supplementary Table 16. Statistically significant results for the 3 digestion traits using GTEx and eQTLGen data and SMR analysis18.  
eQTL 
Data 





Gene Top SNP A1/
A2 
Freq PGWAS PeQTL bSMR PSMR PHEIDI HEIDI 
pass 
GTEx PUD Stomach ENSG000001
67653.4 
8 143757934 PSCA rs2976388 A/G 0.42 1.8E-14 8.8E-41 -0.12 3.0E-11 0.59 Yes 
ENSG000001
76920.10 












12 56395694 SUOX rs1873914 C/G 0.42 4.8E-08 0.0E+00 0.08 6.2E-08 0.74 Yes 
IBD ENSG000002
24203 
1 161507154 RPS23P10 rs9427403 C/A 0.18 3.1E-08 0.0E+00 0.28 4.1E-08 0.06 Yes 
* All listed results are significant after Bonferroni correction at P < 0.05/131,295.
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Supplementary Table 17. Statistically significant results for PUD using blood mQTL data from McRae et al.19 and SMR analysis18. 
mQTL 
Data 














PUD cg08900798 11 1029938 rs59257210 T/C 0.12 9.6E-10 8.6E-42 -0.16 2.5E-08 0.06 Yes 
PUD cg01656853 19 49199172 rs633372 G/A 0.47 1.2E-12 7.7E-56 0.16 9.6E-11 0.07 Yes 
PUD cg04660111 19 49199234 rs507855 A/G 0.47 6.1E-12 1.5E-57 0.16 2.6E-10 0.05 Yes 
PUD cg08873673 19 49199217 rs2548459 T/C 0.47 1.2E-12 1.8E-40 0.19 3.7E-10 0.19 Yes 
PUD cg11773468 19 49216319 rs12978752 A/C 0.45 8.4E-11 9.5E-52 -0.15 2.4E-09 0.04 Yes 
PUD cg15673069 19 49232542 rs838144 T/C 0.50 1.8E-10 1.0E-40 -0.17 8.6E-09 0.01 Yes 
PUD cg21653641 19 49222892 rs35866622 C/T 0.50 7.4E-13 1.9E-16 0.31 6.4E-08 0.04 Yes 
PUD cg01652021 8 143851375 rs4736300 A/G 0.31 2.1E-07 4.5E-167 0.07 3.3E-07 0.08 Yes 
PUD cg09147065 8 143815906 rs2257796 C/T 0.48 1.0E-10 2.5E-16 -0.27 3.9E-07 0.01 Yes 
PUD cg09552631 8 143763326 rs2585183 G/C 0.42 6.9E-14 4.3E-21 -0.28 4.5E-09 0.19 Yes 
PUD cg14304364 8 143807962 rs2164308 T/C 0.49 1.4E-10 4.4E-20 -0.24 1.4E-07 0.08 Yes 
PUD cg24023258 8 143781297 rs2585175 G/C 0.51 3.3E-10 1.5E-73 -0.12 2.9E-09 0.03 Yes 
PUD cg11879188 9 136149908 rs582094 T/A 0.32 3.2E-09 2.1E-183 -0.08 6.6E-09 0.59 Yes 
PUD cg13506600 9 136150361 rs687621 G/A 0.32 1.3E-09 1.5E-79 -0.11 7.5E-09 0.26 Yes 
PUD cg13531387 9 136078657 rs2769071 G/A 0.32 3.0E-09 1.7E-38 0.15 6.9E-08 0.30 Yes 
PUD cg14271713 9 136153846 rs529565 C/T 0.32 2.7E-09 4.2E-45 0.14 4.2E-08 0.65 Yes 
PUD cg21160290 9 136149941 rs554833 T/C 0.32 3.6E-09 0.0E+00 -0.05 4.4E-09 0.48 Yes 
PUD cg22535403 9 136150032 rs554833 T/C 0.32 3.6E-09 0.0E+00 -0.05 4.5E-09 0.37 Yes 
PUD cg24267699 9 136151359 rs582094 T/A 0.32 3.2E-09 1.5E-162 -0.08 7.2E-09 0.43 Yes 
* All listed results are significant after Bonferroni correction at P < 0.05/92,715. 
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Supplementary Table 18. Results of gene sets enrichment analysis at FDR < 5% for each of PG+M and IBD using 
MAGMA20. 
Trait Gene sets name No. of 
genes* 
beta† SE‡ P§ -log10(P) 
PG+M GO POSTSYNAPSE 582 0.19 0.040 9.3E-07 6.03 
GO POSTSYNAPTIC MEMBRANE 302 0.24 0.057 1.3E-05 4.89 
GO SYNAPSE PART 891 0.13 0.032 1.6E-05 4.78 
GO SYNAPSE 1116 0.12 0.029 1.8E-05 4.75 
GO AXON PART 358 0.19 0.052 1.0E-04 4.00 
GO SYNAPTIC MEMBRANE 404 0.18 0.049 1.0E-04 4.00 
GO NEURON PROJECTION 1233 0.10 0.028 1.0E-04 3.98 
GO DENDRITIC TREE 558 0.15 0.041 1.1E-04 3.97 
GO NEURON PART 1629 0.09 0.024 1.4E-04 3.85 
GO GLUTAMATERGIC SYNAPSE 331 0.18 0.052 2.6E-04 3.58 
GO SOMATODENDRITIC 
COMPARTMENT 
778 0.11 0.035 4.4E-04 3.36 
IBD GO MHC CLASS II PROTEIN COMPLEX 14 1.27 0.290 6.4E-06 5.19 
GO MHC PROTEIN COMPLEX 22 0.85 0.203 1.5E-05 4.82 
GO SIDE OF MEMBRANE 480 0.17 0.043 5.8E-05 4.24 
GO LUMENAL SIDE OF MEMBRANE 29 0.68 0.193 2.0E-04 3.70 
GO HOST CELL CYTOPLASM 6 1.52 0.433 2.3E-04 3.64 
GO ER TO GOLGI TRANSPORT VESICLE 
MEMBRANE 
56 0.45 0.130 2.7E-04 3.58 
* The number of genes in the gene-based summary statistics that are also in the gene sets. 
† The regression coefficient of the gene set. 
‡ The standard error of the regression coefficient. 
§ The competitive gene set P value.
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Supplementary Table 19. Number of cases and controls for the 4 digestion phenotypes and 8 depression 
phenotypes and 2 by 2 contingency table for number of cases and controls of each of the 32 digestion-
depression phenotype pairs*. 
  GORD PUD IBS IBD 
  
GPpsy 
Case Control Case Control Case Control Case Control 
40514 305450 12194 333770 22138 323826 5263 340701 
Case 118966 18117 100849 5076 113890 12195 106771 1897 117069 
Control 226998 22397 204601 7118 219880 9943 217055 3366 223632 
Psypsy 
Case Control Case Control Case Control Case Control 
40646 306156 12227 334575 22218 324584 5268 341534 
Case 40262 6571 33691 2056 38206 4381 35881 689 39573 
Control 306540 34075 272465 10171 296369 17837 288703 4579 301961 
DepAll 
Case Control Case Control Case Control Case Control 
9458 74053 2672 80839 5096 78415 1167 82344 
Case 22414 3272 19142 875 21539 2162 20252 327 22087 
Control 61097 6186 54911 1797 59300 2934 58163 840 60257 
SelfRepDep 
Case Control Case Control Case Control Case Control 
36975 223316 11195 249096 19868 240423 4983 255308 
Case 19914 3624 16290 1052 18862 2543 17371 333 19581 
Control 240377 33351 207026 10143 230234 17325 223052 4650 235727 
ICD10Dep 
Case Control Case Control Case Control Case Control 
38095 232382 11536 258941 20032 250445 5052 265425 
Case 9947 2424 7523 804 9143 1461 8486 249 9698 
Control 260530 35671 224859 10732 249798 18571 241959 4803 255727 
LifetimeMDD 
Case Control Case Control Case Control Case Control 
6614 60205 1763 65056 3749 63070 865 65954 
Case 16945 2252 14693 527 16418 1717 15228 264 16681 
Control 49874 4362 45512 1236 48638 2032 47842 601 49273 
MDDRecur 
Case Control Case Control Case Control Case Control 
5790 54207 1560 58437 3167 56830 766 59231 
Case 10216 1437 8779 330 9886 1144 9072 166 10050 
Control 49781 4353 45428 1230 48551 2023 47758 600 49181 
GPNoDep 
Case Control Case Control Case Control Case Control 
6150 54652 1786 59016 2905 57897 834 59968 
Case 9066 1289 7777 341 8725 813 8253 132 8934 
Control 51736 4861 46875 1445 50291 2092 49644 702 51034 
* Cells with blue colour represent eight depression phenotypes following definition of Cai et al.21 and 
corresponding number of cases and controls and cells with orange colour represent four digestion phenotypes 
and corresponding number of cases and controls. Cells with red colour represent the number of overlapped 
cases and controls for each of 32 digestion-depression phenotype pairs. 
Abbreviation: Seen general practice (GP) for nerves, anxiety, tension or depression (GPpsy); Seen psychiatrist 
for nerves, anxiety, tension or depression (Psypsy); Probable recurrent major depression or single probable 
major depression episode (DepAll); Self-reported depression (SelfRepDep); ICD10 defined depression 
(ICD10Dep); DSM-V clinical guideline defined major depression (LifetimeMDD); Major depression recurrence 
(MDDRecur); Seen GP for depression but no cardinal symptoms (GPNoDep); Peptic ulcer disease (PUD); 
Gastro-oesophageal reflux disease (GORD); Irritable bowel syndrome (IBS) and Inflammatory bowel disease 
(IBD).
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Supplementary Table 20. Results of odds ratio and corresponding P value from 2 by 2 contingency table 





Beta s.e. P OR CIL* CIU* 
GPpsy PUD 0.32 0.019 0.0E+00 1.38 1.33 1.43 
GPpsy GORD 0.50 0.011 0.0E+00 1.64 1.61 1.68 
GPpsy IBS 0.91 0.014 0.0E+00 2.49 2.43 2.56 
GPpsy IBD 0.07 0.029 1.1E-02 1.08 1.02 1.14 
Psypsy PUD 0.45 0.025 0.0E+00 1.57 1.49 1.65 
Psypsy GORD 0.44 0.015 0.0E+00 1.56 1.52 1.60 
Psypsy IBS 0.68 0.018 0.0E+00 1.98 1.91 2.05 
Psypsy IBD 0.14 0.041 7.9E-04 1.15 1.06 1.24 
DepAll PUD 0.29 0.042 2.5E-12 1.34 1.23 1.46 
DepAll GORD 0.42 0.023 0.0E+00 1.52 1.45 1.59 
DepAll IBS 0.75 0.029 0.0E+00 2.12 2.00 2.24 
DepAll IBD 0.06 0.066 3.6E-01 1.06 0.93 1.21 
SelfRepDep PUD 0.24 0.033 1.2E-12 1.27 1.19 1.35 
SelfRepDep GORD 0.32 0.019 0.0E+00 1.38 1.33 1.43 
SelfRepDep IBS 0.63 0.023 0.0E+00 1.88 1.80 1.97 
SelfRepDep IBD -0.15 0.057 9.4E-03 0.86 0.77 0.96 
ICD10Dep PUD 0.72 0.038 0.0E+00 2.05 1.90 2.21 
ICD10Dep GORD 0.71 0.024 0.0E+00 2.03 1.94 2.13 
ICD10Dep IBS 0.81 0.029 0.0E+00 2.24 2.12 2.38 
ICD10Dep IBD 0.31 0.066 1.8E-06 1.37 1.20 1.56 
LifetimeMDD PUD 0.23 0.053 9.3E-06 1.26 1.14 1.40 
LifetimeMDD GORD 0.47 0.028 0.0E+00 1.60 1.51 1.69 
LifetimeMDD IBS 0.98 0.034 0.0E+00 2.65 2.48 2.84 
LifetimeMDD IBD 0.26 0.074 4.5E-04 1.30 1.12 1.50 
MDDRecur PUD 0.28 0.063 1.1E-05 1.32 1.16 1.49 
MDDRecur GORD 0.54 0.033 0.0E+00 1.71 1.60 1.82 
MDDRecur IBS 1.09 0.039 0.0E+00 2.98 2.76 3.21 
MDDRecur IBD 0.30 0.088 5.8E-04 1.35 1.14 1.61 
GPNoDep PUD 0.31 0.061 4.7E-07 1.36 1.21 1.53 
GPNoDep GORD 0.47 0.034 0.0E+00 1.60 1.50 1.71 
GPNoDep IBS 0.85 0.043 0.0E+00 2.34 2.15 2.54 
GPNoDep IBD 0.07 0.096 4.5E-01 1.07 0.89 1.30 
* CIL and CIU represent the lower and upper value for 95% confidence interval (CI), respectively. 
Abbreviation: Seen general practice (GP) for nerves, anxiety, tension or depression (GPpsy); Seen psychiatrist 
for nerves, anxiety, tension or depression (Psypsy); Probable recurrent major depression or single probable 
major depression episode (DepAll); Self-reported depression (SelfRepDep); ICD10 defined depression 
(ICD10Dep); DSM-V clinical guideline defined major depression (LifetimeMDD); Major depression recurrence 
(MDDRecur); Seen GP for depression but no cardinal symptoms (GPNoDep); Peptic ulcer disease (PUD); 
Gastro-oesophageal reflux disease (GORD); Irritable bowel syndrome (IBS) and Inflammatory bowel disease 
(IBD).
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Supplementary Table 21. Results of investigating the causality hypothesis between major depression and five digestion phenotypes using Generalised Summary-data-based 
Mendelian Randomisation23. (GSMR, see Fig. 6b) 
Trait1 Trait2 Direction Trait1 -> Trait 2* Direction Trait2 -> Trait 1† 




Major depression PUD 0.18 0.063 3.9E-03 33 0.01§ 0.020 8.0E-01 13 5.0E-07 
0.018 0.023 4.4E-01 8# 5.0E-08 
Major depression GORD 0.21 0.038 2.2E-08 32 0.18 0.036 7.3E-07 17 5.0E-07 
Major depression PG+M 0.24 0.030 2.5E-15 33 0.23 0.038 2.7E-09 18 5.0E-08 
Major depression IBS 0.39 0.050 6.4E-15 33 0.11 0.033 8.9E-04 12 2.0E-06 
Major depression IBD 0.08 0.097 4.0E-01 33 0.01 0.008 1.1E-01 31 5.0E-08 
* The direction represents using trait 1 as exposure to investigate the causality hypothesis on trait 2. 
† The direction represents using trait 2 as exposure to investigate the causality hypothesis on trait 1. 
‡ The unit represents per standard deviation change in liability to the exposure trait. 
§ Yellow highlighted cells indicate use of a relaxed significance threshold for genetic instrument inclusion in the Trait2 -> Trait1 analysis, specified in the significance 
threshold column. 
# Given the unidirectional statistically significant GSMR results between major depression and PUD (i.e., Major depression -> PUD) and relaxed significance threshold for the 
reverse direction (PUD -> Major depression) to obtain SNPs  > 10, we also conducted GSMR analyses using 8 genome-wide significant SNPs for PUD. It remains 
unidirectional statistically significant for GSMR between major depression and PUD, suggesting that major depression is putatively causal for PUD. This analyses should be 
revisited when we have more genome-wide significant SNPs for PUD. 
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Supplementary Table 22. Results of investigating the causality hypothesis between major depression (MD) and PG+M using different Mendelian Randomization (MR) 
methods. 
Exposure Outcome Method No. of SNPs b* se P Egger intercept (se) Egger intercept P 
MD PG+M Inverse variance weighted 34 0.24 0.03 1.9E-12 - - 
MD PG+M MR Egger 34 0.10 0.14 4.8E-01 0.005 (0.005) 2.8E-1 
MD PG+M Weighted median 34 0.23 0.05 3.2E-07 - - 
MD PG+M MR-PRESSO 34 0.24 0.03 4.7E-08† - - 
PG+M MD Inverse variance weighted 19 0.23 0.05 2.5E-06 - - 
PG+M MD MR Egger 19 0.01 0.23 9.6E-01 0.008 (0.008) 3.4E-1 
PG+M MD Weighted median 19 0.19 0.06 1.9E-03 - - 
PG+M MD MR-PRESSO 19 0.23 0.05 1.8E-04† - - 
* The beta is the original value from the corresponding MR analysis. The unit represents per standard deviation change in liability to the exposure trait. 
† No MR-PRESSO (Pleiotropy Residual Sum and Outlier) outliers were detected. 
Abbreviation: MR: mendelian randomization; PG+M: phenotype for peptic ulcer disease, gastro-oesophageal reflux disease with the combination of taking corresponding 
medications/treatments. 
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Supplementary Table 23. Results for the relationship between major depression (MD) and PG+M after controlling EA, BMI and smoking-related traits using Generalised 





Conditional trait(s) for 
exposure trait 
bxy* SExy P No. of SNPs 
MD PG+M EA 0.22 0.03 2.7e-13 32 
BMI 0.27 0.04 3.6e-14 26 
Smoking (Age of Initiation, 
Cigarettes Per Day, Smoking 
Cessation and Smoking 
Initiation) 
0.24 0.03 2.7e-15 33 
EA + BMI + Smoking 0.26 0.04 4.4e-13 25 
PG+M MD EA 0.15 0.05 2.5e-03 11 
BMI 0.20 0.04 7.9e-07 16 
Smoking (Age of Initiation, 
Cigarettes Per Day, Smoking 
Cessation and Smoking 
Initiation) 
0.23 0.04 2.7e-09 18 
EA + BMI + Smoking 0.19 0.05 4.7e-04 9† 
* The unit represents per standard deviation change in liability to the exposure trait. 
† GSMR requires at least 10 SNPs as genetic instrument for exposure. After controlling for EA, BMI and smoking-related traits, only 9 SNPs retained, we used these 9 SNPs 
as genetic instrument rather than relaxing the significance threshold to obtain more SNPs.
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Supplementary Table 24. LCV8 results for the relationship between PG+M (trait 1) and major depression (MD) (trait 2). 
LCV output Value Meaning 
zscore -1.17 Z score for partial genetic causality. zscore>>0 implies gcp>0 
pval.gcpzero.2tailed* 0.24 2-tailed p-value for null that gcp=0 
gcp.pm -0.11 genetic causality proportion (gcp)  
posterior mean gcp (gcp=1: trait 1 -> trait 2; gcp=-1: trait 2-> trait 1) 
gcp.pse 0.09 posterior standard error for gcp 
rho.est 0.43 estimated genetic correlation 
rho.err 0.03 standard error of rho estimate 
pval.fullycausal* 3.5E-46 for MD -> PG+M and 8.1E-26 for 
PG+M -> MD 
[2 entries], p-values for null that gcp=1 or that gcp=-1, respectively 
h2.zscore 34.1 for PG+M and 33.6 for MD [2 entries], z scores for trait 1 and trait 2 being heritable, respectively 
* Since pval.gcpzero.2tailed is non-significant and pval.fullycausal is significant in both directions these results provide no evidence for causal directional relationships.
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Supplementary Table 25. Genetic correlation estimates between major depression and each of the five GI-
DepComRMV phenotypes from bivariate LD score regression analysis15. 




PUD 16666 439661 0.37 0.045 2.1E-16 
PUD-DepComRMV 9345 279469 0.24 0.050 2.1E-6 
GORD 54854 401473 0.37 0.027 3.3E-41 
GORD-DepComRMV 29090 259724 0.29 0.036 4.1E-16 
PG+M 90175 366152 0.43 0.024 1.4E-74 
PG+M-DepComRMV 48180 240634 0.34 0.029 8.6E-29 
IBS 28518 426803 0.49 0.042 1.1E-31 
IBS-DepComRMV 12033 276269 0.37 0.066 1.6E-8 
IBD 7045 449282 0.15 0.043 0.0003 
IBD-DepComRMV 4272 284542 0.18 0.057 0.0018 
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Supplementary Table 26. Results of investigating the causality hypothesis between major depression and each of the five GI-DepComRMV phenotypes using Generalised 
Summary-data-based Mendelian Randomisation23 (GSMR). 




bxy‡ se p No. of SNPs Trait2 
Sensitivity 
Phenotype  
bxy‡ se p No. of SNPs 
Major depression PUD 0.18 0.063 3.9E-03 33 PUD-
DepComRMV 
0.08 0.084 0.366 33 
Major depression GORD 0.21 0.038 2.2E-08 32 GORD-
DepComRMV 
0.25 0.050 8.3E-7 33 
Major depression PG+M 0.24 0.030 2.5E-15 33 PG+M-
DepComRMV 
0.20 0.040 6.1E-7 33 
Major depression IBS 0.39 0.050 6.4E-15 33 IBS-
DepComRMV 
0.36 0.076 2.3E-6 33 
Major depression IBD 0.08 0.097 4.0E-01 33 IBD-
DepComRMV 
0.12 0.124 0.342 33 
* The direction represents using trait 1 as exposure to investigate the causality hypothesis on trait 2 original phenotype. 
† The direction represents using trait 1 as exposure to investigate the causality hypothesis on trait 2 sensitivity phenotype. 
‡ The unit represents per standard deviation change in liability to the exposure trait. 
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Supplementary Table 27. Results of investigating the causality hypothesis between major depression and eight PUD sensitivity phenotypes using Generalised Summary-
data-based Mendelian Randomisation23 (GSMR). 
Trait1 Direction Trait1 -> Trait 2* 
Trait2  No. of cases No. of Controls bxy† se p No. of SNPs 
Major depression PUD 16666 439661 0.18 0.063 3.9E-03 33 
Major depression PUD-GPpsyRMV 9790 290105 0.09 0.083 0.30 33 
Major depression PUD-PsypsyRMV 13867 390048 0.17 0.070 0.018 33 
Major depression PUD-DepAllRMV 15533 411862 0.20 0.066 0.002 33 
Major depression PUD-SelfRepDepRMV 15235 414915 0.17 0.067 0.010 33 
Major depression PUD-ICD10DepRMV 15566 427451 0.18 0.066 0.008 33 
Major depression PUD-LifetimeMddRMV 15972 418474 0.18 0.066 0.005 33 
Major depression PUD-MddRecurRMV 16227 426918 0.17 0.065 0.008 33 
Major depression PUD-GPNoDepRMV 16196 428425 0.18 0.065 0.008 33 
* The direction represents using trait 1 as exposure to investigate the causality hypothesis on trait 2. 
† The unit represents per standard deviation change in liability to the exposure trait. 
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Supplementary Table 28. Polygenic score for major depression* predicts PG+M (peptic ulcer disease (PUD), gastro-oesophageal reflux disease (GORD) in combination with 
medications/treatments for PUD and GORD) risk using logistic regression model. 
Clumping Range Sample Prevalence (P) Sample Size (N) P value of case-control 
polygenic score 
difference 
AUC ORD10† ORD10 CI‡ 
0-5.0E-08 0.198 456327 4.7E-13 0.508 1.08 1.05-1.12 
0-1.0E-05 1.5E-45 0.515 1.19 1.15-1.23 
0-1.0E-04 2.6E-63 0.517 1.26 1.22-1.30 
0-1.0E-03 4.0E-89 0.521 1.30 1.26-1.34 
0-1.0E-02 2.2E-118 0.525 1.33 1.29-1.38 
0-5.0E-02 3.0E-87 0.521 1.29 1.25-1.34 
0-1.0E-01 1.6E-93 0.522 1.29 1.25-1.33 
0-5.0E-01 8.6E-87 0.521 1.26 1.22-1.30 
* The GWAS summary statistics data for major depression are from Wray et al.24 (European ancestry and UK Biobank participants were excluded). 
† The odds ratio of PG+M risk for participants with polygenic score at 10th decile compared with participants with polygenic score at 1st decile. 
‡ 95% confidence interval for the odds ratio at 10th decile.
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Supplementary Table 29. Summary statistics for UKB peptic ulcer diseases genome-wide associated significant SNPs (P < 5e-8) after mtCOJO analyses23 conditional on UKB 
gastro-oesophageal reflux diseases GWAS summary statistics (P < 5e-8). 








UKB statistics after 
mtCOJO analyses23 on 
GORD GWAS summary 
statistics 
OR* P OR* P OR* P 
PUD rs681343 19 49206462 C/T 0.49 0.92 1.9E-15 1.00 7.8E-1 0.91 8.6E-16 
rs2976388 8 143760256 G/A 0.58 1.09 1.8E-14 1.02 2.3E-4 1.08 1.2E-12 
rs10500661 11 6273744 T/C 0.80 0.90 4.1E-14 0.98 2.1E-3 0.91 1.4E-12 
rs147048677 1 155161794 C/T 0.94 0.86 9.0E-12 1.00 7.6E-1 0.86 9.8E-12 
rs78459074 11 1029905 A/G 0.89 1.12 2.6E-10 0.99 1.6E-1 1.13 4.4E-11 
rs34074411 17 39867248 C/T 0.56 0.93 2.6E-10 1.00 7.4E-1 0.93 1.4E-10 
rs687621 9 136137065 A/G 0.68 1.08 1.3E-09 1.00 2.6E-1 1.07 3.0E-09 
rs9581957 13 28557889 C/T 0.68 0.93 3.6E-09 1.00 7.2E-1 0.93 2.0E-09 




Supplementary Fig. 1. Full workflow of the study.
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Genetic correlation (Supplementary 




Gene set enrichment 
(Supplementary Table 18)
Heritability enrichment analysis by 
genomic features (Supplementary 
Table 12 and Supplementary Fig. 11)
Heritability enrichment analysis by 
cell type group and cell specific 
expression (Supplementary Table 
13-15, Fig. 5)







Risk prediction in relatives and heritability estimation (Fig. 1, Table 1)
SMR (Supplementary Table 16, 17)
Post-GWAS
Comorbidity analyses (Fig. 1)
Polygenic score prediction 
(Supplementary Table 28, Fig. 6c, 
6d)
PUD GORD PG+M IBS IBD
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Supplementary Fig. 2. Manhattan plot for IBD. SNPs with red diamond represent genome-wide statistically 
significant independent loci (P < 5.0E-8) for each trait. SNPs highlighted with yellow colour, bold and italic font 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Fig. 3. Quantile-Quantile (Q-Q) plots for the five digestion phenotypes. The λGC  is directly calculated using median χ2 on all the SNPs divided by 0.455 (the 


















Supplementary Fig. 4. Regional association plot for peptic ulcer disease.
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Supplementary Fig. 6. Regional association plots of peptic ulcer disease, gastroesophageal reflux disease and 






















Supplementary Fig. 8. Regional association plot of inflammatory bowel diseases. 
 55 
 
Supplementary Fig. 9. SNP-based heritability and genetic correlation for PUD, GORD, IBS and IBD after 
removing the overlapped individuals using LD score regression analyses14,15. Panel a. Venn diagram for the 
number of overlapped individuals among PUD, GORD, IBS and IBD cases. Panel b. Comparison of SNP-based 
heritability on observed and liability scale for PUD, GORD, IBS and IBD between the original phenotypes and 
phenotypes generated after removing individuals with more than one disorder (defined as sensitivity analysis 
phenotypes). “RO” represents removing overlapped individuals with more than one disorder. We took sample 
risk, i.e. the proportion cases for each phenotype in the UKB cohort, as the population lifetime risk to calculate 
the SNP-based heritability on the liability scale for each digestion phenotype; the sample risk percentage is 
shown below x axis. The error bars represent 95% confidence intervals for the estimated SNP-based 
heritability. “*” represents that the SNP-based heritability was still significant after Bonferroni correction (P < 
0.05/16). Panel c. Genetic correlation between sensitivity analysis phenotypes with the original phenotypes, 
within sensitivity analysis phenotypes, between sensitivity analysis phenotypes with traits from LD Hub and 
published neuro-psychiatric disorder studies. “*” represents that genetic correlation estimate was still 
significant after Bonferroni correction (P < 0.05/(4*4+4*258+4*9)) while “√” represents the P value for genetic 
correlation between IBS (RO) and PUD (RO) estimates < 0.05. Panel d. The number of overlapped individuals 
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rg = 0.33, P = 3.0E-4









































































phenotypes generated after removing the 1740 individuals with both PUD and IBS. “RTO” represents removing 
the 1740 individuals with both PUD and IBS. The sample risk percentage, as shown below axis, was used as the 
population lifetime risk to calculate the SNP-based heritability on the liability scale. The error bars represent 
95% CIs for the estimated SNP-based heritability.
 57 
 
Supplementary Fig. 10a. The process for generation of subgroup phenotypes for each of PUD, GORD and IBS. 
Supplementary Fig. 10b. Summary statistics for rs10512344 from GWAS analyses of IBS and the three 
subgroup phenotypes of IBS using BOLT-LMM11. Supplementary Fig. 10c. SNP-based heritability estimates and 
95% confidence intervals from LD score regression14 for self-report, primary care and hospital admission 




















































Scale Liability Scale Observed Scale
PUD
16,666 cases 439,661 controls
6,934 hospital 
admission only cases
2,978 primary care 
only cases 




Primary Care only 
phenotype
Self Report only 
phenotype
GORD
54,854 cases 401,473 controls
22,983 hospital 
admission only cases
7,506 primary care 
only cases 




Primary Care only 
phenotype
Self Report only 
phenotype
IBS
29,524 cases 426,803 controls
4,003 hospital 
admission only cases
12,739 primary care 
only cases 




Primary Care only 
phenotype
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* P value < 0.05/48
√ P value < 0.05
d
SNP Trait CHR BP A1/A2
A1 
frequency BETA SE P
P for male 
GWAS





9 109009495 G/C 0.96
-0.038 0.056 5.0E-01 - -
IBS Primary Care -0.030 0.032 3.5E-01 - -
IBS Self Report -0.157 0.040 9.1E-05 - -



























































Disease PUD GORD IBS
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statistical P value for the corresponding SNP-based heritability less than 0.05 and “**” represents that the 
statistical P value for the corresponding SNP-based heritability less than 0.05/24 (after Bonferroni correction). 
Supplementary Fig. 10d. Genetic correlation among self-report, primary care, hospital admission subgroup 
phenotypes and the original phenotype for each of PUD, GORD and IBS using bivariate LD score regression15. 
Supplementary Fig. 10e. The effect size of genome-wide significant SNPs from broad definition of PUD, GORD 
and IBS in hospital admission subgroup phenotype versus those in self report subgroup phenotype and 
primary care subgroup phenotype, respectively. Due to the whole-part relationships for each of broadly 
defined phenotype and the corresponding three subgroup phenotypes, as expected, the effect size estimates 
for the SNPs associated with broadly defined phenotype showed high concordance in the GWAS summary 
statistics of the corresponding three subgroup phenotypes.  
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Supplementary Fig. 11. Significant heritability enrichment for GORD, PG+M and IBD of functional annotation 
based on the variants within each category after Bonferroni correction (P < 0.05/(53*5+5*5)). The non-
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Supplementary Fig. 12. Results of SNP and SMR associations across mQTL, eQTL and GWAS for FUT2 gene of 
PUD. The top plot of shows -log10(P) of SNPs from PUD GWAS. The red diamonds and blue circles represent -
log10(P) from SMR test for associations of gene expression and DNAm probes with PUD, respectively. The solid 
diamonds and circles are probes not rejected by the HEIDI test. The second plot shows -log10(P) of the SNP 
association for gene expression FUT2 from the stomach eQTL GTEx25 data. The third plot shows -log10(P) of the 
SNP associations for DNA methylation probe cg01656853, cg04660111 and cg08873673 from blood mQTL data 
of McRae et al.19 (there are no public digestive mQTL data at present). The bottom plot shows Roadmap 











































































































































































































































Supplementary Fig. 13. Plots of the effect sizes of exposure SNPs (x-axis) vs. outcome SNPs (y-axis) (first 
column) and association P values of all the genetic instruments from GWAS for major depression (MD) vs. 
those for each of the five digestion phenotypes (second column). Shown in the third column are the plots 
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Supplementary Fig. 14. Plots of the effect sizes of exposure SNPs (x-axis) vs. outcome SNPs (y-axis) (first 
column) and association P values of all the genetic instruments from GWAS for each of the five digestion 
phenotypes vs. those for major depression (MD) (second column). Shown in the third column are the plots 
of bxy vs. GWAS P value of the five digestion phenotypes at each genetic variant. All the exposure SNPs were 
obtained after HEIDI outlier test. For PUD, GORD and IBS, we relaxed the significance threshold to obtain more 
SNP instruments.



















































































































































































































Supplementary Fig. 15. Mendelian Randomization (MR) plots between major depression and PG+M. Panel a. 
Scatterplot of single-nucleotide polymorphism (SNP) potential effects of major depression on PG+M, with the 
slope of each line corresponding to estimated MR effect per method. Panel b. Forest plot of individual and 
combined SNP MR-estimated effect sizes and 95% confidence intervals (CIs)of major depression on PG+M. The 
raw effect sizes with 95% confidence interval are presented as the dot and horizontal line. Panel c. Scatterplot 
of SNP potential effects of PG+M on major depression, with the slope of each line corresponding to estimated 
MR effect per method. Panel d. Forest plot of individual and combined SNP MR-estimated effect sizes and 95% 
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Supplementary Fig. 16. Polygenic score of peptic ulcer disease (PUD) and irritable bowel syndrome (IBS) 
predicts odds ratio (OR) for PUD (Panel a) and IBS (Panel b) respectively in individuals from GERA cohort using 
logistic regression model. Polygenic score of individuals from GERA cohort were calculated based on PUD 
associated SNPs with P < 5.0E-8 and IBS associated SNPs with P < 0.1 from UKB and converted to deciles (1 = 
lowest, 10 = highest). OR and 95% confidence intervals (CI, orange diamonds and bars) relative to decile 1 
were estimated using logistic regression. The blue dashed lines in a represent that compared with the lowest 
decile, the highest decile have an OR of 1.80 for PUD. The number of PUD cases and controls from GERA 
cohort were 1,004 and 60,843, respectively. The P value for case-control PUD polygenic score difference from 
GERA cohort is 2.5E-6. The blue dashed lines in b represent that compared with the lowest decile, the highest 
decile have an OR of 1.42 for IBS. The number of IBS cases and controls from GERA cohort were 3,359 and 
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